Astellas Gene Therapies
http://www.audentestx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Astellas Gene Therapies
Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.
2023 Will Be A Year Of Partnerships And Acquisitions For Astellas
Astellas’ Mike Luther sees 2023 as a year of growing assets and creating partnerships. The global head of search and evaluation business development told In Vivo about the company's focus on gene and cell therapy and what he thinks makes for a successful business deal.
Scrip Asks...What Does 2023 Hold For Biopharma? Part 2: M&A And Partnering
Deal-making between big pharma and biotech looks set to rise with a looming patent cliff increasing the need for the former to replenish its pipelines. Meanwhile, biotechs need partners to help them advance amid the ongoing big freeze on raising cash on public markets.
Asia Deal Watch: Astellas Invests In Taysha, Gets Rights To Two AAV Gene Therapies
Plus deals involving Takeda/Zedira/Dr. Falk, Lupin/Sunovion, Eucure/Syncromune, Hetero/Johnson & Johnson, Nitto Denko/Omega, Harbour BioMed/CSPC and Pregene/Bone Therapeutics.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
-
Drug Delivery
- Macromolecule
-
Biotechnology
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
-
- Audentes Therapeutics, Inc.
- Cardiogen Sciences, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice